LPCN News and Press, Lipocine Inc.

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study PR Newswire Met standard bioequivalence (BE) criteria C max, AUC 0-t , and AUC 0- ∞ C trough criterion was met LPCN 1154 was well tolerat...

Shares of Lipocine Inc. (NASDAQ: LPCN) traded at a new 52-week high today and are currently trading at $8.96. So far today, approximately 78,318 shares have been exchanged, as compared to an average 30-day volume of 32,701 shares. Lipocine Inc., a clinical-stage biopharmaceutical company, foc...

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024 PR Newswire SALT LAKE CITY , June 10, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that Phase 2 r...

2024-05-09 10:35:08 ET More on Lipocine Seeking Alpha’s Quant Rating on Lipocine Historical earnings data for Lipocine Financial information for Lipocine Read the full article on Seeking Alpha For further details see: Lipocine GAAP EPS of $...

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 PR Newswire SALT LAKE CITY , May 9, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced financial results for the first quarter ended&...

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024 PR Newswire SALT LAKE CITY , May 8, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that data from...

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 PR Newswire Pivotal study design aligned with FDA on streamlined pathway to NDA submission goal in 2024 Topline results anticipated late in 2Q 2024 SALT LAKE CITY ...

2024-04-12 08:32:45 ET More on Pre-market losers & stocks. Candel Therapeutics receives FDA orphan drug designation for its pancreatic cancer treatment Adial stock rallies 81% on data for alcohol abuse drug Seeking Alpha’s Quant Rating on Adial Pharmaceuti...

2024-04-11 09:01:37 ET DENVER, Colo., Apr 11, 2024 ( 247marketnews.com )- Lipocine Inc. (NASDAQ: LPCN ) results from a Phase 2 clinical trial including LPCN 2401, an oral proprietary combination of anabolic androgen receptor agonist and α-tocopherol, an antioxidant, which sho...

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity PR Newswire LPCN 2401 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fa...